ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,245.37
-0.48%
Dow Jones
38,798.99
-0.22%
Gold vs US Dollar
2,293.845
0.00%
Brent Oil
79.395
0.00%
Bitcoin
69,294.99
-0.05%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Viking Therapeutics Inc (VKTX)

  7. Viking Therapeutics Inc (VKTX) News

Viking Therapeutics (VKTX)

Viking Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VKTX
DateTimeSourceHeadlineSymbolCompany
04/06/202412:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VKTXViking Therapeutics Inc
04/06/202412:05PR Newswire (US)Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)NASDAQ:VKTXViking Therapeutics Inc
30/05/202421:03PR Newswire (US)Viking Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:VKTXViking Therapeutics Inc
22/05/202422:12Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:VKTXViking Therapeutics Inc
22/05/202421:33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VKTXViking Therapeutics Inc
24/04/202421:05PR Newswire (US)Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:VKTXViking Therapeutics Inc
24/04/202412:31IH Market NewsU.S. Futures Display Mixed Results Amid Earnings, WTI and Brent Crude Prices Dip in June Futures TradingNASDAQ:VKTXViking Therapeutics Inc
17/04/202421:05PR Newswire (US)Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024NASDAQ:VKTXViking Therapeutics Inc
26/03/202411:03PR Newswire (US)Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735NASDAQ:VKTXViking Therapeutics Inc
05/03/202400:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
05/03/202400:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
04/03/202421:52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VKTXViking Therapeutics Inc
04/03/202421:45PR Newswire (US)Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:VKTXViking Therapeutics Inc
01/03/202421:13Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VKTXViking Therapeutics Inc
29/02/202401:50PR Newswire (US)Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common StockNASDAQ:VKTXViking Therapeutics Inc
27/02/202422:21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VKTXViking Therapeutics Inc
27/02/202421:19PR Newswire (US)Viking Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:VKTXViking Therapeutics Inc
27/02/202412:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VKTXViking Therapeutics Inc
27/02/202412:03PR Newswire (US)Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with ObesityNASDAQ:VKTXViking Therapeutics Inc
10/02/202401:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
09/02/202421:01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VKTXViking Therapeutics Inc
09/02/202400:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
09/02/202400:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
08/02/202421:56Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VKTXViking Therapeutics Inc
08/02/202421:33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VKTXViking Therapeutics Inc
07/02/202422:33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VKTXViking Therapeutics Inc
07/02/202422:24Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VKTXViking Therapeutics Inc
07/02/202421:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VKTXViking Therapeutics Inc
07/02/202421:05PR Newswire (US)Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateNASDAQ:VKTXViking Therapeutics Inc
01/02/202401:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VKTX

Your Recent History

LSE
GKP
Gulf Keystone Petroleum
LSE
POS
Plexus
LSE
LLOY
Lloyds Banking
LSE
SBTX
Skinbiotherapeutics
LSE
GDR
Genedrive
LSE
GOLD
LSE
BIRD
Blackbird
LSE
VAST
Vast Resources
LSE
PANR
Pantheon Resources
LSE
SOLG
Solgold
LSE
EEE
Empire Metals
LSE
SRSP
Sirius Petroleum
LSE
INSG
Insig Ai
LSE
TW.
Taylor Wimpey
LSE
SAR
Sareum
LSE
SHED
Urban Logistics Reit
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved